Methods
At least 6 patients with a recent (< 72h) ICH and hematoma > 2 cm will be recruited. MRgFUS will be used to sonicate the clot leading to lysis. Except for the MRgFUS treatment, ICH patients will receive the same treatment as those not in the trial. Stereotactic aspiration can be added if deemed safe by the treating neurosurgeon. The primary outcome is feasibility (statistical analysis is not proposed); adverse events will be examined and analyzed. Secondary end point is the radiological progression of the clot.
Results and conclusions
We expect that MRgFUS be feasible and safe, and clot size reduction will be seen in most patients. It's possible that the procedure could have some therapeutic value for subjects with few or no other options for treatment.
